Fmr LLC Purchases 6,822 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Fmr LLC raised its holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 23.1% during the third quarter, HoldingsChannel reports. The firm owned 36,416 shares of the company’s stock after acquiring an additional 6,822 shares during the quarter. Fmr LLC’s holdings in Y-mAbs Therapeutics were worth $479,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Dimensional Fund Advisors LP increased its position in Y-mAbs Therapeutics by 15.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after purchasing an additional 65,732 shares in the last quarter. Millennium Management LLC grew its position in Y-mAbs Therapeutics by 23.8% during the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock worth $4,225,000 after acquiring an additional 67,233 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Y-mAbs Therapeutics by 9.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 279,577 shares of the company’s stock valued at $3,676,000 after buying an additional 23,982 shares during the period. Squarepoint Ops LLC raised its holdings in Y-mAbs Therapeutics by 143.4% in the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock valued at $1,527,000 after buying an additional 74,452 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in Y-mAbs Therapeutics by 8.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock worth $1,461,000 after acquiring an additional 8,974 shares during the last quarter. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Trading Down 7.9 %

NASDAQ:YMAB opened at $8.78 on Thursday. Y-mAbs Therapeutics, Inc. has a 12 month low of $6.09 and a 12 month high of $20.90. The stock has a market capitalization of $393.25 million, a price-to-earnings ratio of -16.26 and a beta of 0.61. The firm has a fifty day simple moving average of $12.69 and a two-hundred day simple moving average of $12.65.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The company had revenue of $18.46 million for the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period last year, the company earned ($0.18) EPS. Equities analysts predict that Y-mAbs Therapeutics, Inc. will post -0.66 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

YMAB has been the topic of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. Oppenheimer began coverage on Y-mAbs Therapeutics in a research note on Monday, November 18th. They issued an “outperform” rating and a $23.00 price target for the company. Brookline Capital Management initiated coverage on Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective on the stock. HC Wainwright restated a “buy” rating on shares of Y-mAbs Therapeutics in a research report on Wednesday, December 11th. Finally, Wedbush reiterated an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Y-mAbs Therapeutics has a consensus rating of “Buy” and a consensus price target of $20.89.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.